Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Bo-Rui Chen has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Stair-Climbing Strategy in a Novel Wheel-Legged Hybrid Robot

    by Wei-Ting Chen, En-Chieh Tsui, Wei-Shun Yu, Shao-Yu Chien, Bo-Rui Chen, Pei-Chun Lin

    Stair climbing remains one of the most challenging tasks for autonomous mobile robots, especially in environments with varying step dimensions and limited foothold stability. Existing wheeled robots exhibit high energy efficiency but lack adaptability to discontinuous stairs, while legged robots offer superior stability at the cost of high mechanical and control complexity. To tackle this problem, this paper reports on an adaptive stair-climbing strategy based on a circular finite-state machine (FSM) concept for a novel Wheel-legged hybrid robot, Kilin. The proposed method decomposes the stair-climbing process into three steps — Enter-stair, Mid-stair, and Leave-stair — and divides each step into four states — Fall prevention, Leg rotation, Body raising, and Riser detection — to ensure stability during transitions. The strategy was validated through extensive experiments on various indoor and outdoor stairs of different dimensions. The results demonstrate a high climbing success rate and, in some cases, up to 30% reduction in pitch angle, significantly improving comfort and ease of control compared to conventional legged robots. The proposed approach enables reliable stair traversal and shows strong potential for multi-terrain mobile robot applications.

  • Open Access

    Implementation and Control of a Wheeled Bipedal Robot Using a Fuzzy Logic Approach

    by Chun-Fei Hsu, Bo-Rui Chen, Zi-Ling Lin

    This study designs and implements a wheeled bipedal robot (WBR) that combines the mobility of wheeled robots and the dexterity of legged robots. The designed WBR has extra knee joints to maintain body balance when encountering uneven terrain. Because of the robot’s highly nonlinear, dynamic, unstable, and under-actuated nature, an intelligent motion and balance controller (IMBC) based on a fuzzy logic approach is proposed to maintain the balance of the WBR while it is standing and moving on the ground. It should be emphasized that the proposed IMBC system does not require prior knowledge of system dynamics and the controller parameters are tuned using the qualitative aspects of human knowledge. Furthermore, a 32-bit microcontroller that has memory, programmable I/O peripherals, and a processor core is used to implement the IMBC method. Finally, moving and rotating, height-changing, posture-keeping, and “one leg on slope” movement scenarios are tested to demonstrate the feasibility of the proposed IMBC system. The experimental results show that, by using the proposed IMBC system, the WBR can not only balance and move well both on flat ground and in complex terrain but also extend each leg independently to maintain body balance.


  • Open Access

    A JAK/STAT-mediated inflammatory signaling cascade drives oncogenesis in AF10-rearranged AML

    by Bo-Rui Chen, Anagha Deshpande, Karina Barbosa, Maria Kleppe, Xue Lei, Narayana Yeddula, Pablo Sánchez Vela, Alexandre Rosa Campos, Robert J. Wechsler-Reya, Anindya Bagchi, et al.

    Leukemias bearing fusions of the AF10/MLLT10 gene are associated with poor prognosis, and therapies targeting these fusion proteins (FPs) are lacking. To understand mechanisms underlying AF10 fusion-mediated leukemogenesis, we generated inducible mouse models of acute myeloid leukemia (AML) driven by the most common AF10 FPs, PICALM/CALM-AF10 and KMT2A/MLL-AF10, and performed comprehensive characterization of the disease using transcriptomic, epigenomic, proteomic, and functional genomic approaches. Our studies provide a detailed map of gene networks and protein interactors associated with key AF10 fusions involved in leukemia. Specifically, we report that AF10 fusions activate a cascade of JAK/STAT-mediated inflammatory signaling through direct recruitment of JAK1 kinase. Inhibition of the JAK/STAT signaling by genetic Jak1 deletion or through pharmacological JAK/STAT inhibition elicited potent antioncogenic effects in mouse and human models of AF10 fusion AML. Collectively, our study identifies JAK1 as a tractable therapeutic target in AF10-rearranged leukemias.


  • Open Access

    Design of a Facial Landmark Detection System Using a Dynamic Optical Flow Approach

    by Bing-Fei Wu, Bo-Rui Chen, Chun-Fei Hsu

    Many facial landmark methods based on convolutional neural networks (CNN) have been proposed to achieve favorable detection results. However, the instability landmarks that occur in video frames due to CNNs are extremely sensitive to input image noise. To solve this problem of landmark shaking, this study proposes a simple and effective facial landmark detection method comprising a lightweight U-Net model and a dynamic optical flow (DOF). The DOF uses the fast optical flow to obtain the optical flow vector of the landmark and uses dynamic routing to improve landmark stabilization. A lightweight U-Net model is designed to predict facial landmarks with a smaller model size and less computational complexity. The predicted facial landmarks are further fed to the DOF approach to deal with the unstable shaking. Finally, a comparison of several common methods and the proposed detection method is made on several benchmark datasets. Experimental evaluations and analyses show that not only can the lightweight U-Net model achieve favorable landmark prediction but also the DOF stabilizing method can improve the robustness of landmark prediction in both static images and video frames. It should be emphasized that the proposed detection system exhibits better performance than others without requiring heavy computational loadings.


  • Open Access

    High-Density Domain-Focused CRISPR Screens Reveal Epigenetic Regulators of Hox/Meis Gene Expression in Acute Myeloid Leukemia

    by Karina Barbosa, Anagha Deshpande, Ping Xiang, Bo-Rui Chen, Adam Brown, Neil Robertson, Younguk Sun, John Doench, Peter D Adams, R. Keith Humphries, et al.

    The aberrant and constitutive activation of the HOXA cluster genes and the their-co-factor MEIS1 (HOX/MEIS) is a recurrent feature in several types of myeloid and lymphoid leukemias. Aberrant HOX/MEIS expression has been shown to drive limitless leukemia stem cell self-renewal and is therefore an attractive target for therapy in acute myeloid leukemia (AML). However, since HOX/MEIS genes encode DNA-binding transcription factors, small molecules targeting these proteins directly are lacking. Furthermore, targeting the HOX/MEIS network is complicated by the fact that these genes are coordinately regulated and have redundant functions in sustaining leukemic self-renewal. One way of therapeutically targeting aberrant HOX/MEIS transcription is the identification and pharmacologic inhibition of upstream chromatin regulators that coordinately modulate their expression. In order to identify such chromatin regulators, we made use of an endogenous GFP reporter knocked-in to the MEIS1 locus in the high HOX/MEIS-expressing U937 human AML cell line. Using this system, we first performed a high-throughput flow-cytometry-based small-molecule inhibitor screen with a library of 261 compounds targeting epigenetic regulators. In our screen, the most potent hits that reproducibly showed >50% MEIS1-GFP inhibition were small molecules that targeted DOT1L, the histone methyltransferase. DOT1L inhibitors have already been well-characterized as HOX/MEIS regulators and most epigenetic regulators are not targeted by existing compound libraries. Therefore, we decided to use a genetic screening approach to more extensively interrogate the landscape of epigenetic regulators of HOX/MEIS expression in AML. For this, we designed a custom computational pipeline and built a CRISPR library of 10,000 sgRNAs targeting functionally conserved protein domains of all catalogued chromatin modulatory proteins (> 600 proteins - 5 sgRNAs per conserved domain). This list of epigenetic regulators included histone modifying enzymes, chromatin readers, nucleosome remodelers, adaptor proteins and proteins involved in DNA and RNA modifications, as well as other transcriptional regulators. Using this comprehensive, domain-focused CRISPR library, we conducted a phenotypic enrichment screen. Specifically, we used flow cytometry to purify the top 20% GFP-MEIS1 (high) and bottom 20% GFP-MEIS1 (low) expressing cells and identified sgRNAs that were enriched particularly in the GFP-MEIS1 -low vs -high fraction using next generation sequencing. Given the extent and complexity of the CRISPR library, our approach uncovered members of six distinct chromatin modifying complexes as MEIS1 regulators (MAGeCKFlute pipeline, 2 SD > mean) and we could validate > 10 of these hits as bonafide regulators of MEIS1 as well as HOXA genes. We also demonstrated their essentiality for the proliferation of HOX-driven AML cells using arrayed sgRNA competition assays. These validated hits included several known as well as novel chromatin readers and writers amenable to small-molecule targeting. We focused our attention on the KAT7/JADE3 complex and the casein kinase 2 (CK2) family that we validated as potent and selective regulators of HOX/MEIS expression in AML cells. Our studies demonstrated that genetic depletion of components of the KAT7 complex or of the CK2 family could reverse HOX/MEIS activation in human AML cells, leading to a progressive loss of proliferative potential. Importantly, the use of the clinical-grade CK2 inhibitor CX4945 (Silmitasertib) caused a concentration-dependent down-regulation of HOX/MEIS expression in models of HOX-driven AML, leading to significant anti-leukemia effects. Our study provides a framework for the multiplexed identification of actionable dependencies targeting therapeutically recalcitrant oncogenic networks in cancer. Specifically for AML, since Silmitasertib is in Phase 2 trials for treatment of other cancers, our studies may solve the long-standing problem of targeting leukemia stem cells in AML potentially overcoming therapy refractoriness in this devastating disease. Disclosures: No relevant conflicts of interest to declare.